Alimera Sciences, Inc. (ALIM) NASDAQ
5.54
-0.01(-0.18%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Alimera Sciences, Inc.
Address
6310 Town Square
Alpharetta, GA 30005
United States of America (the)
Phone
678 990 5740
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
154
First IPO Date
November 04, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Richard S. Eiswirth Jr. | Chief Executive Officer & Director | 949,272 | 1968 |
| Jason Werner | Chief Operating Officer | 225,659 | 1978 |
| David R. Holland | Co-Founder, Chief Marketing Officer and Senior Vice President of Corporate Communications & Managed Markets | 413,500 | 1964 |
| Philip Ashman | President of International Operations | 516,981 | 1965 |
| Elliot Maltz | Chief Financial Officer & Treasurer | 0 | 1985 |
| Christopher S. Visick | Vice President, General Counsel & Secretary | 0 | N/A |
| David Dyer | Chief Retina Specialist | 0 | N/A |
| Todd Michael Wood | President of U.S. Operations | 0 | 1969 |
Description
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. for the development and sale of insert technology to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans or to treat diabetic macular edema. The company was incorporated in 2003 and is headquartered in Alpharetta, Georgia.
